AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19026036
Drug: Midostaurin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 75 mg twice daily
Trial: 16189072
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) 800 mg/day
Trial: 12925463
Drug: Acetylcholine (ACh;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh; an endothelium‐dependent vasodilator) administered via transdermal iontophoresis in infants born at term (n=19)
Trial: 12925463
Drug: Acetylcholine (ACh;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh; an endothelium‐dependent vasodilator) administered via transdermal iontophoresis in infants born preterm (n=35)
Trial: 8263271
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g table salt)
Trial: 8263271
Drug: Sucrose capsule
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose capsule (1 g sucrose)
Trial: 8263271
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2000 mg)
Trial: 24731521
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (2 g over 20 minutes)
Trial: 24731521
Drug: Nebulised magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised magnesium sulphate (3 × 500 mg over 1 hour)
Trial: 24731521
Drug: Placebo (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard therapy alone)
Trial: 24731521
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate vs Placebo
Trial: 21152828
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Trifolium pratense, 1 capsule/day
Trial: 21152828
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules containing lactose, 1 capsule/day
Trial: 18257183
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Prostat Tablets)
Trial: 12637480
Drug: Intravenous irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous irinotecan (40 to 125 mg/m2 every 2 weeks) plus oral ciclosporin (5 mg/kg bid for 3 days)
Trial: 12637480
Drug: Intravenous irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous irinotecan
Trial: 10533946
Drug: Education intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Education intervention on antibiotic use
Trial: 7368972
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment after onset of symptoms
Trial: 6098034
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g im) plus daily placebo injections with probenicid (1 g orally)
Trial: 6098034
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g im on each of three days) plus probenicid (1 g orally)
Trial: 6098034
Drug: Single-dose cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose cefotaxime (1 g im) plus probenicid (1 g orally)
Trial: 23160441
Drug: Daily lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily lens replacement each morning
Trial: 23160441
Drug: Monthly lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly lens replacement (historical control)
Trial: 15809409
Drug: Continuation medication
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation medication
Trial: 1451927
Drug: Sultamicillin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sultamicillin (50 mg/kg in two equal doses each day for a mean of 10 days)
Trial: 1451927
Drug: Cefaclor (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (40 mg/kg in three equal doses each day for a mean of 11 days)
Trial: 30808022
Drug: GDNF (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDNF (120 μg per putamen)
Trial: 27093771
Drug: Sodium perborate
RxNorm normalized name: Sodium Perborate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium perborate solution for 5 minutes per day combined with brushing
Trial: 27093771
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine digluconate solution for 5 minutes per day combined with brushing
Trial: 25410068
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anesthesia (7.5 mg hypobaric bupivacaine)
Trial: 25410068
Drug: Bilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral spinal anesthesia (12 mg hypobaric bupivacaine)
Trial: 18319308
Drug: Estrogen-progestin treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-progestin treatment (EPT)
Trial: 15944847
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg o.d.)
Trial: 15944847
Drug: Amoxicillin-clavulanate (1,000/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (1,000/125 mg t.i.d.) plus roxithromycin (150 mg b.i.d.)
Trial: 12866746
Drug: Diane 35
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane 35 plus CPA (cyproterone acetate [2 mg] and ethinyl estradiol [35 microg])
Trial: 12866746
Drug: Diane 35
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane 35 plus spironolactone [100 mg]
Trial: 12866746
Drug: Spironolactone [100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone [100 mg] alone
Trial: 23168373
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate diet (8 g CHO per kg body mass)
Trial: 23168373
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate diet (3 g CHO per kg body mass)
Trial: 20880596
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 30 mg kg(‐1) in saline (20 mL)
Trial: 18854793
Drug: Lidocaine +
RxNorm normalized name: Lidocaine + Menthol Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine + Ketorolac (30 mg)
Trial: 18854793
Drug: Lidocaine +
RxNorm normalized name: Lidocaine + Menthol Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine + Ketorolac (30 mg) + Dexamethasone (8 mg)
Trial: 18854793
Drug: Lidocaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (3 mg x kg‐1)
Trial: 1814322
Drug: Oestradiol (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol (4, 2, or 1 mg) + Norethisterone acetate (1 mg)
Trial: 1814322
Drug: Oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol valerate (2 mg) + Cyproterone acetate (1 mg) + Calcium (1000 mg)
Trial: 6359851
Drug: Nadolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (80 to 240 mg)
Trial: 6359851
Drug: Bendroflumethiazide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide (5 to 10 mg)
Trial: 6359851
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bendroflumethiazide and Nadolol (B + N)
Trial: 28992526
Drug: Pharmacogenetics-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetics-guided treatment
Trial: 26559142
Drug: Laser‐1st treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser‐1st treatment (Selective laser trabeculoplasty)
Trial: 26559142
Drug: Medicine‐1st treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine‐1st treatment (IOP-lowering drops)
Trial: 17031643
Drug: Doc-Gem (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doc-Gem (gemcitabine 900 mg/m² on days 1 and 8, docetaxel 75 mg/m² on day 1, every 3 weeks for up to six cycles)
Trial: 17031643
Drug: Cis-Gem->Doc (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cis-Gem->Doc (gemcitabine 900 mg/m² on days 1 and 8, cisplatin 70 mg/m² on day 1 for three cycles, followed by docetaxel 100 mg/m² on day 1 for three cycles)
Trial: 11235929
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean daily dose = 3.8 mg)
Trial: 11235929
Drug: Pimozide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide (mean daily dose = 2.9 mg)
Trial: 25686338
Drug: Traditional ABCS
RxNorm normalized name: ABC
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Traditional ABCS plus an extra intraoral suture at points G.lat.
Trial: 19404210
Drug: XM02 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XM02 (5 microg/kg/d, subcutaneous daily injections for at least 5 days and a maximum of 14 days)
Trial: 19404210
Drug: Filgrastim Neupogen
RxNorm normalized name: filgrastim Injection [Neupogen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim Neupogen (5 microg/kg/d, subcutaneous daily injections for at least 5 days and a maximum of 14 days)
Trial: 16894934
Drug: Compound Glycyrrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Glycyrrhizin for 6 months
Trial: 11453879
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose heparinization (400 IU/kg) with standard uncoated ECC (Group A)
Trial: 11453879
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose heparinization (400 IU/kg) with heparin-coated ECC (Group B)
Trial: 11453879
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparinization (150 IU/kg) with heparin-coated ECC (Group C)
Trial: 11453879
Drug: Heparin-coated ECC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated ECC with low dose systemic heparinization
Trial: 1416135
Drug: alfentanil 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 30 micrograms/kg followed by propofol 2 mg/kg IV
Trial: 1416135
Drug: alfentanil 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 40 micrograms/kg followed by propofol 2 mg/kg IV
Trial: 1416135
Drug: alfentanil 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 50 micrograms/kg followed by propofol 2 mg/kg IV
Trial: 1416135
Drug: alfentanil 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 60 micrograms/kg followed by propofol 2 mg/kg IV
Trial: 1416135
Drug: d‐tubocurarine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐tubocurarine 3 mg, thiamylal 4 mg/kg, and succinylcholine 1 mg/kg IV (Group I)
Trial: 29782065
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 25 mcg
Trial: 17585664
Drug: Low frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low frequency pulse plus auricular point magnetic therapy
Trial: 16225652
Drug: Continuous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous prednisolone treatment during the entire induction phase
Trial: 16225652
Drug: Prednisolone given
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone given for 2 weeks of each cycle in combination with VMCP-IFN-alpha 2b
Trial: 11872200
Drug: 1 mg/d
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/d 17beta‐estradiol orally for 90 days
Trial: 10211871
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intravenous (i.v.) infusion of zaleplon
Trial: 10211871
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg intravenous (i.v.) infusion of zaleplon
Trial: 10211871
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral dose of zaleplon
Trial: 10211871
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous (i.v.) infusion of zaleplon
Trial: 7796762
Drug: Chemotherapy, community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy, community mobilization to effect change in water contact habits and faecal disposal
Trial: 7192119
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 60 mg LCB-29
Trial: 7192119
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 400 mg LCB-29
Trial: 7192119
Drug: Ointment application
RxNorm normalized name: Nasal Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment application of 400 mg or 7 X 200 mg LCB-29
Trial: 29402402
Drug: Caffeine gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine gum (200 mg) administered at 01:00 h, 03:00 h, 05:00 h, and 07:00 h during sleep deprivation
Trial: 29402402
Drug: Caffeine gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine gum (200 mg)
Trial: 28095883
Drug: Altitudes plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Altitudes plus Specialist Treatment as Usual (STAU)
Trial: 28095883
Drug: Specialist Treatment
RxNorm normalized name: Centrum Specialist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialist Treatment as Usual (STAU) alone
Trial: 25965709
Drug: Oral losmapimod
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral losmapimod (7.5 mg twice daily)
Trial: 19689569
Drug: Born to
RxNorm normalized name: Born To Be Mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Born to Learn (BTL) curriculum conducted in monthly home visits
Trial: 15319622
Drug: Hypotonic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic oral rehydration solution (ORS) with non-digestible carbohydrates (NDC)
Trial: 15319622
Drug: Hypotonic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic oral rehydration solution (ORS) without non-digestible carbohydrates (NDC)
Trial: 9590463
Drug: L-2-oxothiazolidine-4-carboxylic acid
RxNorm normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-2-oxothiazolidine-4-carboxylic acid (OTC) 1,500 mg
Trial: 9590463
Drug: L-2-oxothiazolidine-4-carboxylic acid
RxNorm normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-2-oxothiazolidine-4-carboxylic acid (OTC) 3,000 mg
Trial: 7929870
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral valproate after a 750 mg intravenous loading dose
Trial: 7929870
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of valproate after a 750 mg loading dose
Trial: 7929870
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and intravenous regimens
Trial: 3300408
Drug: naloxone 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone 0.05 mg
Trial: 29263150
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ezetimibe/simvastatin (E/S)
Trial: 29263150
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg placebo/simvastatin
Trial: 24037890
Drug: 4 months
RxNorm normalized name: leuprolide 30 mg/4 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 months of recombinant FSH (rFSH) pretreatment followed by 24 months of pulsatile GnRH therapy
Trial: 24037890
Drug: Pulsatile GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile GnRH therapy alone for 24 months
Trial: 12668982
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at 13-15 mg/kg/d for 6 months
Trial: 10370357
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose ondansetron (0.6 mg/kg, maximum dose 32 mg)
Trial: 10370357
Drug: Multiple standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple standard-dose ondansetron (0.15 mg/kg, maximum dose 8 mg, every 4 hr for four doses)
Trial: 8911803
Drug: Sulfate-free electrolyte
RxNorm normalized name: Aminosyn 7 % with Electrolytes, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfate-free electrolyte lavage solution (SF-ELS)
Trial: 8911803
Drug: Standard polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard polyethylene glycol (PEG) solution
Trial: 1867232
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 or 40 mg once or twice a day)
Trial: 6617905
Drug: CC-hCG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-hCG plus dehydrogesterone (group 1)
Trial: 6617905
Drug: CC-hCG (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-hCG (group 2)
Trial: 28474286
Drug: Electronic tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic tablet animations
Trial: 23865593
Drug: Feedback group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback group (receiving accelerometer-based feedback of daily walking activity)
Trial: 21329631
Drug: heparin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin 1,000 IU/ml
Trial: 21329631
Drug: heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin 5,000 IU/ml
Trial: 15363874
Drug: Oral ibandronate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate, 50mg once daily
Trial: 11182748
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) started immediately after surgery
Trial: 11182748
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion during surgery and for 24 hours postoperatively
Trial: 7997919
Drug: Functional restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional restoration program (treatment group)
Trial: 3196530
Drug: Dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate sodium 145 mEq/L
Trial: 3196530
Drug: Dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate sodium 150 mEq/L
Trial: 3196530
Drug: Dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate sodium 155 mEq/L
Trial: 3196530
Drug: Dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate sodium 145 mEq/L to 155 mEq/L
Trial: 31747355
Drug: Vitafusion® Power
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitafusion® Power C gummy (1000 mg)
Trial: 31747355
Drug: Comparator caplet
RxNorm normalized name: Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator caplet (1000 mg)
Trial: 30640777
Drug: Aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminolevulinic acid photodynamic therapy (ALA-PDT)
Trial: 30640777
Drug: Vehicle photodynamic
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle photodynamic therapy (VEH-PDT)
Trial: 25862116
Drug: 9‐mg sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9‐mg sustained release (SR) melatonin for four weeks
Trial: 18283176
Drug: ABT‐874 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐874 200 mg once at week 0
Trial: 18283176
Drug: ABT‐874 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐874 100 mg every other week for 12 weeks
Trial: 18283176
Drug: ABT‐874 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐874 200 mg weekly for 4 weeks
Trial: 18283176
Drug: ABT‐874 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐874 200 mg every other week for 12 weeks
Trial: 18283176
Drug: ABT‐874 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐874 200 mg weekly for 12 weeks
Trial: 12666468
Drug: Group Treatment
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Treatment Control (GC)